# Liberate Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liberate-bio

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.liberatebio.com
- Total disclosed funding: $31M
- Latest round: Seed (Oct 15, 2025)
- Investors on record: 1

## About

Liberate Bio, based in the US, develops innovative in vivo genetic medicine delivery solutions, focusing on enhancing the efficacy of mRNA, CRISPR, and gene editing technologies.Founded in 2022, Liberate Bio is headquartered in Boston, US, and specializes in advanced genetic therapies. The company has secured USD 31.00 mn in Seed funding from Khosla Ventures as of October 2025. It has completed one total deal to date.Liberate Bio specializes in advanced genetic medicine delivery through its proprietary RAPTOR™ platform. This innovative system is designed to facilitate extrahepatic delivery of genetic therapies at an unmatched industrial scale, thereby enhancing the efficacy and reach of mRNA, CRISPR, and gene editing technologies. The key end use cases being addressed by the company include the treatment of various genetic disorders and enhancing the therapeutic potential of genetic medicines. Liberate Bio's client base primarily includes biopharmaceutical companies and research institutions engaged in genetic therapy development. Their products are targeted towards global markets, particularly in North America, Europe, and select regions in Asia, reflecting a diverse geographical footprint in the biopharmaceutical sector.Liberate Bio generates revenue through partnerships with biopharmaceutical companies that utilize the RAPTOR™ platform for their genetic medicine development needs. The company's transaction structure is primarily B2B, focusing on collaborations and licensing agreements to enable other firms to leverage its delivery technology. These partnerships may involve milestone payments and royalties based on the success of developed therapies utilizing the RAPTOR™ platform. Specific pricing plans and contract terms are tailored to each partnership and are informed by the unique value proposition of the RAPTOR™ technology, which is designed to optimize the delivery of genetic treatments. The firm’s revenue streams are closely tied to the adoption rates of its technology across its client base, emphasizing its role in advancing gene therapy applications.In October 2025, Liberate Bio raised USD 31.00 mn in Seed funding from Khosla Ventures. The company will utilize this funding to advance its in vivo CAR–M therapy into clinical trials and further develop its AI-driven lipid nanoparticle platform. Plans for growth include launching new products focused on enhancing genetic therapy delivery and expanding into additional markets in North America and Europe by 2026.

## Funding rounds

- Seed, Oct 15, 2025, $31M — Khosla Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed